Endpoints 11 is an annual recognition of the most promising next-generation private biotech companies, selected by Endpoints News' editor John Carroll, with the most recent ceremony held in Boston4.
During the biotech sector challenges in 2025—including funding slowdowns and heightened investor caution—former Endpoints 11 winners faced a difficult market, like much of the industry13.
Xaira Therapeutics, an Endpoints 11 winner recognized in 2024, drew attention as one of biotech's largest AI-driven startups with top-tier investors, and is referenced as continuing to make scientific and business progress into late 20245.
Endpoints and industry partners have hosted several panels and expert discussions in 2025 focusing on funding, clinical development, and market adaptation strategies, with insights on how elite companies (including past winners) are navigating the downturn13.
While overall capital inflows and IPO activity have declined industry-wide, panelists and surveys referenced by Endpoints indicate leading private biotechs—such as past Endpoints 11 winners—are relying on strategic partnerships and pipeline resilience to weather the climate, but specific fates and performance metrics for individual winners have not been publicly detailed in search-accessible recaps134.
Sources:
1. https://endpoints.studio/events/
3. https://events.endpts.com/top-100-vcs-2025